Chapter 6 128 Magnesium oxide (n =46) Magnesium sulfate (n =46) Magnesium citrate (n =46) 24-wk Mean, mm Hg 93 ± 10 96 ± 11 97 ± 11 Difference vs magnesium citrate 0 (-1; 2) 0 (-2; 2) .. Pulse pressure 2-wk Mean, mm Hg 50 ± 10 51 ± 10 53 ± 9 Difference vs magnesium citrate 1 (-2; 3) 1 (-1; 3) .. 12-wk Mean, mm Hg 49 ± 9 51 ± 9 53 ± 10 Difference vs magnesium citrate 1 (-3; 2) -1 (-3; 2) .. 24-wk Mean, mm Hg 51 ± 11 52 ± 10 54 ± 10 Difference vs magnesium citrate 0 (-2; 2) 1 (-1; 3) .. Heart rate 2-wk Mean, bpm 59 ± 8 59 ± 7 61 ± 8 Difference vs magnesium citrate -1 (-3; 1) -0 (-2; 1) .. 12-wk Mean, bpm 59 ± 7 60 ± 6 61 ± 8 Difference vs magnesium citrate -1 (-3; 0) -0 (-2; 1) .. 24-wk Mean, bpm 59 ± 7 59 ± 6 62 ± 8 Difference vs magnesium citrate -3 (-5; -1)** -2 (-3; -0) .. Values are mean ± SD. Adjusted mean differences (90% CIs) were obtained from linear mixed-effect models with age, sex, baseline value of the outcome of interest, time, intervention, and the interaction time × intervention as fixed effects. SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean arterial pressure, PP; pulse pressure, HR; heart rate. ** P<0.01 (one-sided P values). Subgroup analyses As secondary post hoc analyses, we assessed whether the effect of magnesium citrate, magnesium oxide and magnesium sulfate vs placebo on c-fPWV was modified by age, sex, BMI, waist circumference, use of diuretics, dyslipidemia, hypertension, or baseline c-fPWV (Figure 2). We found that the effect on c-fPWV of magnesium citrate vs placebo and of magnesium oxide vs placebo was significantly modified by age; the effect of magnesium oxide vs placebo was significantly modified by BMI; the effect of magnesium citrate vs placebo was significantly modified by dyslipidemia; and the effect of magnesium Table 6. (Continued)
RkJQdWJsaXNoZXIy MTk4NDMw